Drug Profile
Research programme: pain therapeutics - Maruho
Alternative Names: T-type calcium channel/voltage-gated sodium channel blocker - MaruhoLatest Information Update: 14 Oct 2022
Price :
$50
*
At a glance
- Originator RaQualia Pharma
- Developer Maruho; RaQualia Pharma
- Class Analgesics
- Mechanism of Action Sodium channel antagonists; T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
- Research Inflammatory pain; Pruritus
Most Recent Events
- 14 Oct 2022 Early research is ongoing in Inflammatory-pain in Japan (RaQualia Pharma pipeline, October 2022)
- 14 Oct 2022 Preclinical development is ongoing in Neuropathic-pain in Japan (RaQualia Pharma pipeline, October 2022)
- 20 Sep 2022 Early research in Pruritus in Japan (unspecified route), prior to September 2022 (RaQualia Pharma pipeline, October 2022)